Forsta AP Fonden Has $23.15 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Forsta AP Fonden trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 52,000 shares of the pharmaceutical company’s stock after selling 6,200 shares during the period. Forsta AP Fonden’s holdings in Vertex Pharmaceuticals were worth $23,150,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Activest Wealth Management acquired a new position in Vertex Pharmaceuticals during the first quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 45 shares in the last quarter. Access Investment Management LLC acquired a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at about $27,000. Flaharty Asset Management LLC acquired a new position in shares of Vertex Pharmaceuticals during the 1st quarter valued at about $32,000. Finally, Legacy Investment Solutions LLC bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $29,000. Institutional investors own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on VRTX shares. Truist Financial set a $490.00 target price on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. UBS Group reduced their price objective on shares of Vertex Pharmaceuticals from $553.00 to $546.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Leerink Partners raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their price objective for the stock from $458.00 to $456.00 in a report on Thursday, September 25th. Wells Fargo & Company upgraded shares of Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 target price on the stock in a research note on Wednesday, August 6th. Finally, HC Wainwright dropped their target price on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $489.10.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $434.19 on Thursday. The company has a market cap of $110.16 billion, a PE ratio of 31.04 and a beta of 0.36. The firm has a fifty day moving average price of $406.47 and a two-hundred day moving average price of $428.20. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the prior year, the business earned $4.38 earnings per share. The firm’s revenue for the quarter was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.